ABSTRACT
HIV-1 full-length RNA (HIV-1 RNA) plays a central role in viral replication, serving as a template for Gag/Gag-Pol translation and as a genome for the progeny virion. To gain a better understanding of the regulatory mechanisms of HIV-1 replication, we adapted a recently described system to visualize and track translation from individual HIV-1 RNA molecules in living cells. We found that, on average, half of the cytoplasmic HIV-1 RNAs are being actively translated at a given time. Furthermore, translating and nontranslating RNAs are well mixed in the cytoplasm; thus, Gag biogenesis occurs throughout the cytoplasm without being constrained to particular subcellular locations. Gag is an RNA binding protein that selects and packages HIV-1 RNA during virus assembly. A long-standing question in HIV-1 gene expression is whether Gag modulates HIV-1 RNA translation. We observed that despite its RNA-binding ability, Gag expression does not alter the proportion of translating HIV-1 RNA. Using single-molecule tracking, we found that both translating and nontranslating RNAs exhibit dynamic cytoplasmic movement and can reach the plasma membrane, the major HIV-1 assembly site. However, Gag selectively packages nontranslating RNA into the assembly complex. These studies illustrate that although HIV-1 RNA serves two functions, as a translation template and as a viral genome, individual RNA molecules carry out only one function at a time. These studies shed light on previously unknown aspects of HIV-1 gene expression and regulation.
Subject(s)
Gene Expression Regulation, Viral , HIV-1/physiology , RNA, Viral/metabolism , Virus Assembly , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , Cell Membrane/metabolism , Cytoplasm/metabolism , Genome, Viral/genetics , Intravital Microscopy , Microscopy, Fluorescence , Protein Biosynthesis , RNA, Viral/genetics , Virion/metabolism , gag Gene Products, Human Immunodeficiency Virus/geneticsABSTRACT
HIV-1 Gag virus-like particles (VLPs) are promising candidates for the development of future vaccines. Recent viral outbreaks have manifested the need of robust vaccine production platforms able to adapt to new challenges while achieving mass production capacity. For the rapid production of VLPs, the method of transient gene expression (TGE) have proved highly efficient. Based on a previous characterization of the HEK293 cell line upon transient transfection using multiplexed quantitative proteomics, molecular production bottlenecks and metabolic pathways likely to be optimized were identified. In this study, these molecular components and metabolic pathways have been explored and modulated via transient metabolic engineering using approaches like design of experiments to fully exploit and optimize VLP production, transfection and budding efficiency. Upon overexpression of endosomal sorting complex required for transport accessory proteins like NEDD4L and CIT, VLP production increased 3.3 and 2.9-fold, respectively. Overexpression of glycosphingolipid precursor enzyme UGCG improved transfection efficiency by 17% and knocking-down the Gag-binding protein CNP improved 2.5-fold VLP specific productivity. Combining CNP inhibition and UGCG overexpression further improved budding efficiency by 37.3%. Modulating VLP production and accessory pathways like intracellular budding, demonstrated the potential of metabolic engineering to optimize and intensify the development of robust production platforms for future vaccines.
Subject(s)
AIDS Vaccines , HIV-1 , Metabolic Engineering , Transfection , Vaccines, Virus-Like Particle , gag Gene Products, Human Immunodeficiency Virus , AIDS Vaccines/biosynthesis , AIDS Vaccines/genetics , HEK293 Cells , HIV-1/genetics , HIV-1/metabolism , Humans , Vaccines, Virus-Like Particle/biosynthesis , Vaccines, Virus-Like Particle/genetics , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , gag Gene Products, Human Immunodeficiency Virus/geneticsABSTRACT
Translation initiation of the human immunodeficiency virus type-1 (HIV-1) full-length RNA has been shown to occur through cap-dependent and IRES-driven mechanisms. Previous studies suggested that the nuclear cap-binding complex (CBC) rather than eIF4E drives cap-dependent translation of the full-length RNA and we have recently reported that the CBC subunit CBP80 supports the function of the viral protein Rev during nuclear export and translation of this viral transcript. Ribosome recruitment during CBC-dependent translation of cellular mRNAs relies on the activity CBP80/20 translation initiation factor (CTIF), which bridges CBP80 and the 40S ribosomal subunit through interactions with eIF3g. Here, we report that CTIF inhibits HIV-1 and HIV-2 Gag synthesis from the full-length RNA. Our results indicate that CTIF associates with HIV-1 Rev through its N-terminal domain and is recruited onto the full-length RNA ribonucleoprotein complex in order to interfere with Gag synthesis. We also demonstrate that CTIF induces the cytoplasmic accumulation of Rev impeding the association of the viral protein with CBP80. We finally show that Rev interferes with the association of CTIF with CBP80 indicating that CTIF and Rev compete for the CBC subunit.
Subject(s)
Eukaryotic Initiation Factors/physiology , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , rev Gene Products, Human Immunodeficiency Virus/antagonists & inhibitors , Cells, Cultured , Down-Regulation , HEK293 Cells , HIV-1/genetics , HIV-1/metabolism , HeLa Cells , Humans , Jurkat Cells , Protein Biosynthesis/genetics , rev Gene Products, Human Immunodeficiency Virus/physiologyABSTRACT
The nature of enveloped virus-like particles (VLPs) has triggered high interest in their application to different research fields, including vaccine development. The baculovirus expression vector system (BEVS) has been used as an efficient platform for obtaining large amounts of these complex nanoparticles. To date, most of the studies dealing with VLP production by recombinant baculovirus infection utilize indirect detection or quantification techniques that hinder the appropriate characterization of the process and product. Here, we propose the application of cutting-edge quantification methodologies in combination with advanced statistical designs to exploit the full potential of the High Five/BEVS as a platform to produce HIV-1 Gag VLPs. The synergies between CCI, MOI, and TOH were studied using a response surface methodology approach on four different response functions: baculovirus infection, VLP production, VLP assembly, and VLP productivity. TOH and MOI proved to be the major influencing factors in contrast with previous reported data. Interestingly, a remarkable competition between Gag VLP production and non-assembled Gag was detected. Also, the use of nanoparticle tracking analysis and flow virometry revealed the existence of remarkable quantities of extracellular vesicles. The different responses of the study were combined to determine two global optimum conditions, one aiming to maximize the VLP titer (quantity) and the second aiming to find a compromise between VLP yield and the ratio of assembled VLPs (quality). This study provides a valuable approach to optimize VLP production and demonstrates that the High Five/BEVS can support mass production of Gag VLPs and potentially other complex nanoparticles.
Subject(s)
HIV-1/immunology , Nanoparticles/analysis , Vaccines, Virus-Like Particle/analysis , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , Animals , Baculoviridae , Cell Line , Data Interpretation, Statistical , Extracellular Vesicles , HEK293 Cells , Humans , Insecta/cytology , Insecta/virology , Microscopy, Electron , Nanoparticles/chemistry , Vaccines, Virus-Like Particle/ultrastructure , VirionABSTRACT
Gag synthesis from the full-length unspliced mRNA is critical for the production of the viral progeny during human immunodeficiency virus type-1 (HIV-1) replication. While most spliced mRNAs follow the canonical gene expression pathway in which the recruitment of the nuclear cap-binding complex (CBC) and the exon junction complex (EJC) largely stimulates the rates of nuclear export and translation, the unspliced mRNA relies on the viral protein Rev to reach the cytoplasm and recruit the host translational machinery. Here, we confirm that Rev ensures high levels of Gag synthesis by driving nuclear export and translation of the unspliced mRNA. These functions of Rev are supported by the CBC subunit CBP80, which binds Rev and the unspliced mRNA in the nucleus and the cytoplasm. We also demonstrate that Rev interacts with the DEAD-box RNA helicase eIF4AI, which translocates to the nucleus and cooperates with the viral protein to promote Gag synthesis. Finally, we show that the Rev/RRE axis is important for the assembly of a CBP80-eIF4AI complex onto the unspliced mRNA. Together, our results provide further evidence towards the understanding of the molecular mechanisms by which Rev drives Gag synthesis from the unspliced mRNA during HIV-1 replication.
Subject(s)
Eukaryotic Initiation Factor-4A/genetics , HIV-1/genetics , Nuclear Cap-Binding Protein Complex/genetics , RNA, Messenger/genetics , gag Gene Products, Human Immunodeficiency Virus/genetics , rev Gene Products, Human Immunodeficiency Virus/genetics , Cell Line , Eukaryotic Initiation Factor-4A/metabolism , HIV-1/metabolism , HeLa Cells , Humans , Multiprotein Complexes/genetics , Multiprotein Complexes/metabolism , Nuclear Cap-Binding Protein Complex/metabolism , Protein Binding , RNA Splicing , RNA, Messenger/metabolism , RNA, Viral/genetics , RNA, Viral/metabolism , Virus Replication/genetics , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , rev Gene Products, Human Immunodeficiency Virus/metabolismABSTRACT
UNLABELLED: A major goal in HIV eradication research is characterizing the reservoir cells that harbor HIV in the presence of antiretroviral therapy (ART), which reseed viremia after treatment is stopped. In general, it is assumed that the reservoir consists of CD4(+) T cells that express no viral proteins. However, recent findings suggest that this may be an overly simplistic view and that the cells that contribute to the reservoir may be a diverse population that includes both CD4(+) and CD4(-) cells. In this study, we directly infected resting CD4(+) T cells and used fluorescence-activated cell sorting (FACS) and fiber-optic array scanning technology (FAST) to identify and image cells expressing HIV Gag. We found that Gag expression from integrated proviruses occurred in resting cells that lacked surface CD4, likely resulting from Nef- and Env-mediated receptor internalization. We also extended our approach to detect cells expressing HIV proteins in patients suppressed on ART. We found evidence that rare Gag(+) cells persist during ART and that these cells are often negative for CD4. We propose that these double-negative α/ß T cells that express HIV protein may be a component of the long-lived reservoir. IMPORTANCE: A reservoir of infected cells persists in HIV-infected patients during antiretroviral therapy (ART) that leads to rebound of virus if treatment is stopped. In this study, we used flow cytometry and cell imaging to characterize protein expression in HIV-infected resting cells. HIV Gag protein can be directly detected in infected resting cells and occurs with simultaneous loss of CD4, consistent with the expression of additional viral proteins, such as Env and Nef. Gag(+) CD4(-) cells can also be detected in suppressed patients, suggesting that a subset of infected cells express proteins during ART. Understanding the regulation of viral protein expression during ART will be key to designing effective strategies to eradicate HIV reservoirs.
Subject(s)
Anti-Retroviral Agents/therapeutic use , CD4 Antigens/analysis , CD8 Antigens/analysis , HIV Infections/drug therapy , HIV Infections/virology , T-Lymphocyte Subsets/virology , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , Flow Cytometry , Humans , Optical Imaging , T-Lymphocyte Subsets/chemistryABSTRACT
During the post-transcriptional events of the HIV-2 replication cycle, the full-length unspliced genomic RNA (gRNA) is first used as an mRNA to synthesize Gag and Gag-Pol proteins and then packaged into progeny virions. However, the mechanisms responsible for the coordinate usage of the gRNA during these two mutually exclusive events are poorly understood. Here, we present evidence showing that HIV-2 expression induces stress granule assembly in cultured cells. This contrasts with HIV-1, which interferes with stress granules assembly even upon induced cellular stress. Moreover, we observed that the RNA-binding protein and stress granules assembly factor TIAR associates with the gRNA to form a TIAR-HIV-2 ribonucleoprotein (TH2RNP) complex localizing diffuse in the cytoplasm or aggregated in stress granules. Although the assembly of TH2RNP in stress granules did not require the binding of the Gag protein to the gRNA, we observed that increased levels of Gag promoted both translational arrest and stress granule assembly. Moreover, HIV-2 Gag also localizes to stress granules in the absence of a 'packageable' gRNA. Our results indicate that the HIV-2 gRNA is compartmentalized in stress granules in the absence of active translation prior to being selected for packaging by the Gag polyprotein.
Subject(s)
Cytoplasmic Granules/virology , HIV-2/genetics , RNA, Viral/metabolism , Virus Assembly , Cytoplasmic Granules/metabolism , Eukaryotic Initiation Factor-2/metabolism , Genome, Viral , HIV-2/physiology , HeLa Cells , Humans , Protein Biosynthesis , RNA, Viral/analysis , RNA, Viral/biosynthesis , RNA-Binding Proteins/chemistry , RNA-Binding Proteins/metabolism , Ribonucleoproteins/metabolism , Stress, Physiological , Virus Replication , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , gag Gene Products, Human Immunodeficiency Virus/geneticsABSTRACT
Tetherin, an interferon-inducible membrane protein, inhibits the release of nascent enveloped viral particles from the surface of infected cells. However, the mechanisms underlying virion retention have not yet been fully delineated. Here, we employ biochemical assays and engineered tetherin proteins to demonstrate conclusively that virion tethers are composed of the tetherin protein itself, and to elucidate the configuration and topology that tetherin adopts during virion entrapment. We demonstrate that tetherin dimers adopt an "axial" configuration, in which pairs of transmembrane domains or pairs of glycosylphosphatidyl inositol anchors are inserted into assembling virion particles, while the remaining pair of membrane anchors remains embedded in the infected cell membrane. We use quantitative western blotting to determine that a few dozen tetherin dimers are used to tether each virion particle, and that there is â¼3- to 5-fold preference for the insertion of glycosylphosphatidyl inositol anchors rather than transmembrane domains into tethered virions. Cumulatively, these results demonstrate that axially configured tetherin homodimers are directly responsible for trapping virions at the cell surface. We suggest that insertion of glycosylphosphatidyl inositol anchors may be preferred so that effector functions that require exposure of the tetherin N-terminus to the cytoplasm of infected cells are retained.
Subject(s)
Antigens, CD/metabolism , Antiviral Agents/metabolism , HIV-1/physiology , Models, Biological , Virion/physiology , Virus Attachment , Antigens, CD/chemistry , Antigens, CD/genetics , Antiviral Agents/chemistry , Dimerization , GPI-Linked Proteins/chemistry , GPI-Linked Proteins/genetics , GPI-Linked Proteins/metabolism , Glycosylphosphatidylinositols/chemistry , Glycosylphosphatidylinositols/metabolism , HEK293 Cells , HIV-1/immunology , HeLa Cells , Human Immunodeficiency Virus Proteins/genetics , Human Immunodeficiency Virus Proteins/metabolism , Humans , Mutation , Peptide Fragments/chemistry , Peptide Fragments/genetics , Peptide Fragments/metabolism , Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase/metabolism , Protein Conformation , Protein Interaction Domains and Motifs , Proteolysis , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/metabolism , Viral Regulatory and Accessory Proteins/genetics , Viral Regulatory and Accessory Proteins/metabolism , Virion/immunology , gag Gene Products, Human Immunodeficiency Virus/biosynthesisABSTRACT
HIV-1 transcription is activated by the Tat protein, which recruits CDK9/cyclin T1 to the HIV-1 promoter. CDK9 is phosphorylated by CDK2, which facilitates formation of the high-molecular-weight positive transcription elongation factor b (P-TEFb) complex. We previously showed that chelation of intracellular iron inhibits CDK2 and CDK9 activities and suppresses HIV-1 transcription, but the mechanism of the inhibition was not understood. In the present study, we tested a set of novel iron chelators for the ability to inhibit HIV-1 transcription and elucidated their mechanism of action. Novel phenyl-1-pyridin-2yl-ethanone (PPY)-based iron chelators were synthesized and examined for their effects on cellular iron, HIV-1 inhibition, and cytotoxicity. Activities of CDK2 and CDK9, expression of CDK9-dependent and CDK2-inhibitory mRNAs, NF-κB expression, and HIV-1- and NF-κB-dependent transcription were determined. PPY-based iron chelators significantly inhibited HIV-1, with minimal cytotoxicity, in cultured and primary cells chronically or acutely infected with HIV-1 subtype B, but they had less of an effect on HIV-1 subtype C. Iron chelators upregulated the expression of IκB-α, with increased accumulation of cytoplasmic NF-κB. The iron chelators inhibited CDK2 activity and reduced the amount of CDK9/cyclin T1 in the large P-TEFb complex. Iron chelators reduced HIV-1 Gag and Env mRNA synthesis but had no effect on HIV-1 reverse transcription. In addition, iron chelators moderately inhibited basal HIV-1 transcription, equally affecting HIV-1 and Sp1- or NF-κB-driven transcription. By virtue of their involvement in targeting several key steps in HIV-1 transcription, these novel iron chelators have the potential for the development of new therapeutics for the treatment of HIV-1 infection.
Subject(s)
Cyclin-Dependent Kinase 2/metabolism , Cyclin-Dependent Kinase 9/metabolism , HIV-1/genetics , I-kappa B Kinase/biosynthesis , Iron Chelating Agents/pharmacology , Cell Line , Cell Survival , Cyclin A/biosynthesis , Cyclin A/genetics , Cyclin E/biosynthesis , Cyclin E/genetics , Cyclin T/biosynthesis , Cyclin-Dependent Kinase 2/antagonists & inhibitors , Cyclin-Dependent Kinase 9/antagonists & inhibitors , Cyclin-Dependent Kinase Inhibitor p21/biosynthesis , Cyclin-Dependent Kinase Inhibitor p21/genetics , Gene Expression Regulation, Viral/drug effects , HEK293 Cells , HIV-1/drug effects , Humans , I-kappa B Kinase/genetics , I-kappa B Kinase/metabolism , RNA, Messenger/biosynthesis , Reverse Transcription/drug effects , S Phase Cell Cycle Checkpoints/drug effects , Transcription Factor RelA/metabolism , Transcription, Genetic/drug effects , Virus Replication/drug effects , env Gene Products, Human Immunodeficiency Virus/biosynthesis , gag Gene Products, Human Immunodeficiency Virus/biosynthesisABSTRACT
Despite the effectiveness of highly active antiretroviral therapy (HAART) in treating individuals infected with HIV, HAART is not a cure. A latent reservoir, composed mainly of resting CD4+T cells, drives viral rebound once therapy is stopped. Understanding the formation and maintenance of latently infected cells could provide clues to eradicating this reservoir. However, there have been discrepancies regarding the susceptibility of resting cells to HIV infection in vitro and in vivo. As we have previously shown that resting CD4+T cells are susceptible to HIV integration, we asked whether these cells were capable of producing viral proteins and if so, why resting cells were incapable of supporting productive infection. To answer this question, we spinoculated resting CD4+T cells with or without prior stimulation, and measured integration, transcription, and translation of viral proteins. We found that resting cells were capable of producing HIV Gag without supporting spreading infection. This block corresponded with low HIV envelope levels both at the level of protein and RNA and was not an artifact of spinoculation. The defect was reversed upon stimulation with IL-7 or CD3/28 beads. Thus, a population of latent cells can produce viral proteins without resulting in spreading infection. These results have implications for therapies targeting the latent reservoir and suggest that some latent cells could be cleared by a robust immune response.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/virology , HIV-1/physiology , Virus Latency , env Gene Products, Human Immunodeficiency Virus/biosynthesis , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , CD28 Antigens/metabolism , CD3 Complex/metabolism , Cells, Cultured , Gene Expression Regulation, Viral , HIV Infections/immunology , HIV-1/immunology , HIV-1/metabolism , Humans , Interleukin-17/metabolism , Interleukin-7/immunology , Macrophage Inflammatory Proteins/immunology , Virus ReplicationABSTRACT
The 5'-untranslated region (5'-UTR) of the genomic RNA of human immunodeficiency viruses type-1 (HIV-1) and type-2 (HIV-2) is composed of highly structured RNA motifs essential for viral replication that are expected to interfere with Gag and Gag-Pol translation. Here, we have analyzed and compared the properties by which the viral 5'-UTR drives translation from the genomic RNA of both human immunodeficiency viruses. Our results showed that translation from the HIV-2 gRNA was very poor compared to that of HIV-1. This was rather due to the intrinsic structural motifs in their respective 5'-UTR without involvement of any viral protein. Further investigation pointed to a different role of TAR RNA, which was much inhibitory for HIV-2 translation. Altogether, these data highlight important structural and functional differences between these two human pathogens.
Subject(s)
5' Untranslated Regions , HIV Long Terminal Repeat , HIV-1/genetics , HIV-2/genetics , Protein Biosynthesis , RNA, Viral/chemistry , Animals , Cell Line , Genome, Viral , HIV-2/metabolism , Humans , Proviruses/genetics , Proviruses/metabolism , Ribosomes/metabolism , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , gag Gene Products, Human Immunodeficiency Virus/geneticsABSTRACT
A determinant of human T-lymphotropic virus-1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) development is the HTLV-1-infected cell burden. Viral proteins Tax and HBZ, encoded by the sense and antisense strands of the pX region, respectively, play key roles in HTLV-1 persistence. Tax drives CD4(+)-T cell clonal expansion and is the immunodominant viral antigen recognized by the immune response. Valproate (2-n-propylpentanoic acid, VPA), a histone deacetylase inhibitor, was thought to trigger Tax expression, thereby exposing the latent HTLV-1 reservoir to immune destruction. We evaluated the impact of VPA on Tax, Gag, and HBZ expressions in cultured lymphocytes from HTLV-1 asymptomatic carriers and HAM/TSP patients. Approximately one-fifth of provirus-positive CD4(+) T cells spontaneously became Tax-positive, but this fraction rose to two-thirds of Tax-positive-infected cells when cultured with VPA. Valproate enhanced Gag-p19 release. Tax- and Gag-mRNA levels peaked spontaneously, before declining concomitantly to HBZ-mRNA increase. VPA enhanced and prolonged Tax-mRNA expression, whereas it blocked HBZ expression. Our findings suggest that, in addition to modulating Tax expression, another mechanism involving HBZ repression might determine the outcome of VPA treatment on HTLV-1-infected-cell proliferation and survival.
Subject(s)
Basic-Leucine Zipper Transcription Factors/biosynthesis , Gene Expression Regulation, Viral/drug effects , Gene Products, tax/biosynthesis , Human T-lymphotropic virus 1/physiology , Valproic Acid/pharmacology , Viral Proteins/biosynthesis , Antisense Elements (Genetics)/drug effects , Apoptosis/drug effects , Asymptomatic Diseases , Basic-Leucine Zipper Transcription Factors/genetics , Cells, Cultured/drug effects , Cells, Cultured/virology , Genes, gag , Genes, pX , Histone Acetyltransferases/antagonists & inhibitors , Humans , Lymphocytes/drug effects , Lymphocytes/virology , Paraparesis, Tropical Spastic , Proviruses/genetics , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , RNA, Viral/biosynthesis , RNA, Viral/genetics , Retroviridae Proteins , Viral Proteins/genetics , gag Gene Products, Human Immunodeficiency Virus/biosynthesisABSTRACT
Translation initiation on most eukaryotic mRNAs occurs via a cap-dependent scanning mechanism and its efficiency is modulated by their 5'-untranslated regions (5'-UTR). The human immunodeficiency virus type 1 (HIV-1) 5'-UTR contains a stable TAR hairpin directly at its 5'-end, which possibly masks the cap structure. In addition, the 5'-UTR is relatively long and contains several stable RNA structures that are essential for viral replication. These characteristics may interfere with ribosomal scanning and suggest that translation is initiated via internal entry of ribosomes. Literature on the HIV-1 5'-UTR-driven translation initiation mechanism is controversial. Both scanning and internal initiation have been shown to occur in various experimental systems. To gain further insight in the translation initiation process, we determined which part of the 5'-UTR is scanned. To do so, we introduced upstream AUGs at various positions across the 5'-UTR and determined the effect on expression of a downstream reporter gene that was placed under control of the gag start codon. This strategy allowed us to determine the window of ribosomal scanning on the HIV-1 5'-UTR.
Subject(s)
5' Untranslated Regions , HIV-1/genetics , Peptide Chain Initiation, Translational , RNA, Viral/chemistry , Base Sequence , Cell Line, Tumor , Codon, Initiator , Genome, Viral , Humans , Molecular Sequence Data , Open Reading Frames , Ribosomes/metabolism , Viral Proteins/metabolism , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , gag Gene Products, Human Immunodeficiency Virus/geneticsABSTRACT
The green fluorescent protein (GFP) is a powerful genetic marking tool that has enabled virologists to monitor and track viral proteins during HIV infection. Expression-optimized Gag-GFP constructs have been used to study virus-like particle (VLP) assembly and localization in cell types that are easily transfected. The development of HIV-1 variants carrying GFP within the context of the viral genome has facilitated the study of infection and has been particularly useful in monitoring the transfer of virus between cells following virological synapse formation. HIV Gag-iGFP, a viral clone that contains GFP inserted between the matrix (MA) and capsid (CA) domains of Gag, is the first replication competent molecular clone that generates fluorescent infectious particles. Here, we discuss some methods that exploit HIV Gag-iGFP to quantify cell-to-cell transmission of virus by flow cytometry and to track the proteins during assembly and transmission using live-cell imaging.
Subject(s)
Cell Tracking/methods , Green Fluorescent Proteins/genetics , HIV Infections/virology , HIV-1/genetics , Cytopathogenic Effect, Viral , Flow Cytometry , Genome, Viral , Host-Pathogen Interactions , Humans , Jurkat Cells , Microscopy, Fluorescence , Organisms, Genetically Modified , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , gag Gene Products, Human Immunodeficiency Virus/geneticsABSTRACT
A wide variety of cell types, including immune cells, have been observed to frequently interact via transient, long-distance membrane connections. However, considerable heterogeneity in their structure, mode of formation and functional properties has emerged, suggesting the existence of distinct subclasses. Open-ended tunneling nanotubes allow for the trafficking of cytoplasmic material, e.g. endocytic vesicles, or the transmission of calcium signals. Closed-ended membrane nanotubes do not seamlessly connect the cytoplasm between two interacting cells and a junction exists within the nanotube or where the nanotube meets a cell body. Recent live cell imaging suggested that membrane nanotubes between T cells could present a novel route for HIV-1 transmission. Here, we describe detailed protocols for observing membrane nanotubes and HIV-1 trafficking by live cell fluorescence microscopy.
Subject(s)
Cell Membrane Structures/ultrastructure , HIV-1/physiology , T-Lymphocytes/ultrastructure , Cell Culture Techniques , Cell Tracking , Fibronectins/metabolism , Fixatives , Green Fluorescent Proteins/biosynthesis , Green Fluorescent Proteins/genetics , Humans , Immunological Synapses/ultrastructure , Jurkat Cells , Microscopy, Confocal , Pseudopodia/ultrastructure , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics , T-Lymphocytes/virology , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , gag Gene Products, Human Immunodeficiency Virus/geneticsABSTRACT
Retroviruses rely on host RNA-binding proteins to modulate various steps in their replication. Previously several animal retroviruses were determined to mediate Dhx9/RNA helicase A (RHA) interaction with a 5' terminal post-transcriptional control element (PCE) for efficient translation. Herein PCE reporter assays determined HTLV-1 and HIV-1 RU5 confer orientation-dependent PCE activity. The effect of Dhx9/RHA down-regulation and rescue with siRNA-resistant RHA on expression of HIV-1(NL4-3) provirus determined that RHA is necessary for efficient HIV-1 RNA translation and requires ATPase-dependent helicase function. Quantitative analysis determined HIV-1 RNA steady-state and cytoplasmic accumulation were not reduced; rather the translational activity of viral RNA was reduced. Western blotting determined that RHA-deficient virions assemble with Lys-tRNA synthetase, exhibit processed reverse transcriptase and contain similar level of viral RNA, but they are poorly infectious on primary lymphocytes and HeLa cells. The results demonstrate RHA is an important host factor within the virus-producer cell and within the viral particle. The identification of RHA-dependent PCE activity in cellular junD RNA and in six of seven genera of Retroviridae suggests conservation of this translational control mechanism among vertebrates, and convergent evolution of Retroviridae to utilize this host mechanism.
Subject(s)
DEAD-box RNA Helicases/physiology , HIV-1/genetics , HIV-1/physiology , Neoplasm Proteins/physiology , Protein Biosynthesis , Virion/physiology , Base Sequence , Cell Line , HIV Long Terminal Repeat , Human T-lymphotropic virus 1/genetics , Humans , Lysine-tRNA Ligase/physiology , Molecular Sequence Data , RNA, Viral/metabolism , Terminal Repeat Sequences , Virus Assembly , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , gag Gene Products, Human Immunodeficiency Virus/geneticsABSTRACT
mRNA vaccines are potentially attractive alternatives to DNA vaccines more often discussed, as they are generally considered safer than their DNA counterparts. The major limitations on the potency of RNA vaccines are their instability and inability to spread in vivo. Virus-like particles (VLPs) based on the bacteriophage MS2 have demonstrated remarkably high stability and may provide an improved platform for RNA-based genetic vaccination. However, no in vivo study of an MS2 VLP-mediated RNA vaccine has been reported. Therefore, we developed a model vaccine wherein MS2 VLPs packaging HIV-1 gag mRNAs (1544 bases) were produced in Saccharomyces cerevisiae, and then, used to immunize BALB/c mice. Serological analyses showed that antigen-specific antibody responses were elicited by immunization. These findings suggest that MS2 VLPs can be used in the design and construction of novel and safe phage-based mRNA delivery vectors.
Subject(s)
RNA, Viral/biosynthesis , RNA, Viral/immunology , Saccharomyces cerevisiae/genetics , Viral Vaccines/biosynthesis , Viral Vaccines/immunology , Virion/immunology , Animals , Antigen-Antibody Reactions , Genetic Vectors , Levivirus/genetics , Mice , Mice, Inbred BALB C , Models, Biological , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , RNA, Messenger/immunology , RNA, Viral/genetics , Viral Vaccines/genetics , Virion/genetics , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , gag Gene Products, Human Immunodeficiency Virus/genetics , gag Gene Products, Human Immunodeficiency Virus/immunologyABSTRACT
One attractive strategy for the development of a human immunodeficiency virus (HIV) vaccine is the use of viral vectors with a proven safety profile and an absence of preexisting immunity in humans, such as Newcastle disease virus (NDV). Several NDV vaccine vectors have been generated, and their immunogenicities have been investigated with different animal models. However, a systematic study to evaluate the optimal insertion site of the foreign antigens into NDV that results in enhanced immune responses specific to the antigen has not yet been conducted. In this article, we describe the ability of NDV expressing HIV Gag to generate a Gag-specific immune response in mice. We also have determined the optimal insertion site into the NDV genome by generating recombinant NDV-HIVGag viruses in which HIV gag was located at different transcriptional positions throughout the NDV viral genome. All recombinant viruses were viable, grew to similar titers in embryonated chicken eggs, and expressed Gag in a stable manner. Our in vivo experiments revealed that higher HIV Gag protein expression positively correlates with an enhanced CD8(+) T-cell-mediated immune response and protective immunity against challenge with vaccinia virus expressing HIV Gag. We also inserted a codon-optimized version of HIV gag in the described best location, between the P and M genes. Virus expressing the codon-optimized version of HIV gag induced a higher expression of the protein and an enhanced immune response against HIV Gag in mice. These results indicate that strategies directed toward increasing antigen expression by NDV result in enhanced immunogenicity and vaccine efficacy.
Subject(s)
AIDS Vaccines/immunology , CD8-Positive T-Lymphocytes/immunology , Gene Expression , Genetic Vectors , Newcastle disease virus/genetics , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , AIDS Vaccines/genetics , Animals , Chick Embryo , Female , Mice , Mice, Inbred BALB C , Microbial Viability , Newcastle disease virus/growth & development , Recombination, Genetic , Vaccinia/prevention & control , Viral Plaque Assay , Viremia/prevention & control , gag Gene Products, Human Immunodeficiency Virus/geneticsABSTRACT
Trichosanthin (TCS) is a type I ribosome-inactivating protein that plays dual role of plant toxin and anti-viral peptide. The sorting mechanism of such an exogenous protein is in long pursuit. Here, we examined TCS trafficking in cells expressing the HIV-1 scaffold protein Gag, and we found that TCS preferentially targets the Gag budding sites at plasma membrane or late endosomes depending on cell types. Lipid raft membrane but not the Gag protein mediates the association of TCS with viral components. After Gag budding, TCS is then released in association with the virus-like particles to generate TCS-enriched virions. The resulting TCS-enriched HIV-1 exhibits severely impaired infectivity. Overall, the observations indicate the existence of a unique and elaborate sorting strategy for hijacking HIV-1.
Subject(s)
Acquired Immunodeficiency Syndrome/therapy , Endosomes/metabolism , HIV-1/metabolism , Trichosanthin/metabolism , Virion/metabolism , Acquired Immunodeficiency Syndrome/virology , Cell Line , Humans , Membrane Microdomains/metabolism , Membrane Microdomains/virology , Protein Transport , Trichosanthin/genetics , gag Gene Products, Human Immunodeficiency Virus/biosynthesis , gag Gene Products, Human Immunodeficiency Virus/geneticsABSTRACT
In this study, we employed a recombinant Mycobacterium bovis Bacille Calmette-Guerin (BCG) harboring whole HIV-1 CRF01_AE gag DNA as a candidate vaccine to investigate specific cell-mediated immunity in BALB/c mice. Construction of the stable expression recombinant BCG was achieved by demonstrating by Western blot detection of protein of approximately 55 kDa. By a single injection of 0.1 mg of the recombinant HIV-1 gag protein expressing BCG subcutaneously into mice, after 2 weeks various specific cytotoxic T-lymphocyte (CTL) responses were exhibited against a single gag epitope of amino acid positions 294-304, and also against various peptide regions along the entire gag protein with moderate CTL activities (10-35% specific cell lysis), which increased to relatively high levels (50-68%) after one month. However, after two months activities were 3-3.7 fold lower. On the other hand, gag-specific lymphocyte proliferation was detected 9.3 fold higher than that of non-immunized mouse spleen cells. Our results indicate that in mice, BCG can be used as a recombinant live vector to induce cellular immune responses to HIV-1 gag antigen.